BGF

DRUG5 trials

Sponsors

AstraZeneca

Conditions

Chronic ObstructiveChronic Obstructive Pulmonary Disease (COPD)Pulmonary DiseasePulmonary Disease, Chronic ObstructiveRetrospective Studies

Phase 3

A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

CompletedNCT03836677

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2019-02-26End: 2019-11-11Updated: 2021-02-11

Unknown Phase

Exacerbations Among Patients Receiving Breztri (EROS Study)

CompletedNCT06514144

AstraZenecaChronic Obstructive, Pulmonary Disease, Retrospective Studies

Start: 2022-10-01End: 2023-03-07Updated: 2024-12-13

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

CompletedNCT06742736

AstraZenecaPulmonary Disease, Chronic Obstructive

Start: 2024-05-31End: 2024-09-30Updated: 2025-08-07

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

CompletedNCT06744374

AstraZenecaPulmonary Disease, Chronic Obstructive

Start: 2024-02-29End: 2024-03-30Updated: 2025-08-27

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

CompletedNCT07103642

AstraZenecaPulmonary Disease, Chronic Obstructive

Start: 2024-08-15End: 2024-10-18Updated: 2025-08-15

Related Papers

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.

2021-07-0111 citations